8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
September 2025 in “Reactions Weekly” 1 citations
,
January 2023 in “Chemical Engineering Journal”
Additive markers are most common and crucial for text coherence.
9 citations
,
March 1989 in “The BMJ” Adding diltiazem to a beta blocker can cause dangerously slow heart rates.
The conclusion cannot be provided because the document content is not available.
5 citations
,
January 2018 The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.
February 2025 in “Iranian journal of pharmaceutical research” April 2015 in “The FASEB Journal” Midazolam's antiseizure effects are mainly due to synaptic GABA-A receptors, not neurosteroids or extrasynaptic receptors.
3 citations
,
February 2018 in “Australian Veterinary Journal” Veterinarians could test positive for ketamine from work exposure, not just substance abuse.
10 citations
,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
Melatonin may protect hair follicle stem cells from damage caused by chemotherapy.
May 2024 in “ABDIKAN Jurnal Pengabdian Masyarakat Bidang Sains dan Teknologi” A family medicine approach improves treatment and quality of life for children with enterobiosis.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
33 citations
,
May 2001 in “Annals of pharmacotherapy/The annals of pharmacotherapy” Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
6 citations
,
November 2018 in “Photodiagnosis and Photodynamic Therapy” A wearable cap-like device using light therapy reduced scalp skin lesions by 71% and was painless.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
9 citations
,
November 1980 in “Geburtshilfe und Frauenheilkunde” Fenoterol treatment causes increased hair growth due to higher metabolism in hair follicles, not hormones.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
June 2008 in “Alcoholism Clinical and Experimental Research” Certain drugs can block changes in brain receptors caused by alcohol withdrawal.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
203 citations
,
December 1947 in “Annals of Internal Medicine”
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.